Researchers halt trial of ReoPro for acute strokes
Centocor and Eli Lilly have temporarily halted a trial of ReoPro for acute strokes as a result of safety concerns. Researchers were investigating ReoPro's effectiveness in dissolving blood clots. Patients in the trial will stop receiving the drug as the researchers evaluate the benefits versus the risks involved in the trial.
- read this AP report for more
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
